Get the Perfect Answer for Synthetic Peptides & Oligonucleotides

ZÁZNAM | Proběhlo Čt, 5.10.2023
Nové terapie, jako jsou syntetické peptidy a oligonukleotidy, přitahují pozornost díky svým schopnostem zlepšovat jejich vlastnosti.
Agilent Technologies: Get the Perfect Answer for Synthetic Peptides & Oligonucleotides

Agilent Technologies: Get the Perfect Answer for Synthetic Peptides & Oligonucleotides

Emerging therapies like Synthetic Peptides & Oligonucleotides are catching the attention due to its capabilities to improve their physicochemical and biological properties, such as efficacy, stability, bioavailability, safety, etc.

These require thorough understanding & analysis of these molecules and exclusive strategies to quantify these molecules in various biological matrices.

Presenter: Dr. Ravi Shah (M.S.; PhD), (Head of the Department - Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research - Ahmedabad)

Dr. Ravi is Head of the Department of pharmaceutical analysis at NIPER- Ahmedabad. He has received his M.S. (Pharm) and PhD from NIPER, Mohali under the guidance of Prof. Saranjit Singh. Before joining back to academic research, he served at various levels in industry to understand the needs of pharma sector. He had started his career with Biocon-BMS research and development center, where he was responsible for analytical activities related to IND and NDA fillings of drug discovery leads. Post drug discovery understanding, he joined Dr. Reddy’s in 2015 as associate director and department head for Analytical R&D Bangalore facility to learn generic drug development. He gathered vast experience on analytical method development, and regulatory requirements pertaining to DMF/ ANDA fillings at US and EU. He also worked significantly on complex generics for getting pharmaceutical equivalence through robust CQA, CPP and CMA correlations through QbD approaches.

He has published many research articles in almost every international analytical journal like Analytical Chemistry, Drug Testing and Analysis, Journal of Chromatogaphy A,Journal of Chromatogaphy B,Journal of Pharmaceutical and Biomedical Analysis, Trends in Analytical Chemistry, Analytical Methods, Analytical and Bioanalytical Chemistry, Rapid communications in mass spectrometry etc.

Presenter: Dr. Ashish Pargaonkar (Biopharma Workflow Commercialization Lead, Agilent Technologies)

Dr. Ashish Pargaonkar is a Lead for Biopharma Workflow Commercialization team for India and also Manager for Centre of Excellences at Bangalore. A Microbiologist by education with a Ph.D, he holds more than 20 years of experience for Biopharma market applications on Hi Resolution Mass Spectrometry. He has a long record of successful demonstrations and customer engagements on workflows for CQA’s, Intact mass, peptide mapping, HCP and Glycans using Agilent state-of-the art solutions. He has authored ASMS posters on media components and therapeutic peptides. Dr. Ashish has been invited speaker at several conferences and workshops at Biosimilar Congress, ADC 2018, IIT (Mumbai, Delhi), ICT (Mumbai), PSI events.

Presenter: Ms. Paramjeet Khandpur (Biopharma Workflow Commercialization Lead, Agilent Techologies)

Paramjeet Khandpur, M.Tech., holds a bachelor’s degree in chemical engineering from VTU University and a Master's in Bioprocess Technology from the Institute of Chemical Technology, Mumbai. Paramjeet is currently the Biopharma Workflow Commercialization Lead at Agilent. In this role, she leverages her expertise to deliver comprehensive workflow solutions and offer support to customers, catering to their analytical requirements across the Biopharma value chain.

Previously, she worked as an Application Engineer at Agilent's Centre of Excellence Lab in Bangalore, specializing in various liquid chromatography platforms. She also collaborated with users in the Pharma and Biopharma industry for method development, troubleshooting, and method transfer.

Agilent Technologies